Seres Therapeutics (NASDAQ:MCRB) Raised to “Hold” at StockNews.com

Seres Therapeutics (NASDAQ:MCRB) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other equities research analysts have also weighed in on MCRB. Chardan Capital reissued a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, JPMorgan Chase & Co. downgraded shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Price Performance

Seres Therapeutics stock opened at $0.91 on Friday. The stock has a market cap of $154.59 million, a PE ratio of -3.94 and a beta of 2.13. The stock’s fifty day moving average is $0.82 and its two-hundred day moving average is $0.90. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $2.05.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Vontobel Holding Ltd. acquired a new stake in shares of Seres Therapeutics in the third quarter valued at approximately $374,000. Geode Capital Management LLC raised its position in Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock valued at $1,314,000 after purchasing an additional 255,014 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Seres Therapeutics by 42.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 222,771 shares during the period. FMR LLC grew its position in Seres Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after purchasing an additional 140,096 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Seres Therapeutics during the 2nd quarter worth $92,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.